New Restriction on Acetaminophen Use

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p94
Trade Publication
The article reports that the Food and Drug Administration (FDA) wants manufacturers of prescription combination products containing acetaminophen to limit the amount of pain reliever to no more than 325 milligrams each tablet per capsule and to update labels of the risk of liver injury in the U.S.


Related Articles

  • FDA mistake delays answer on off-label uses. Dickinson, James G. // Medical Marketing & Media;Feb2002, Vol. 37 Issue 2, p30 

    Reports on the delayed answer of the U.S. Food and Drug Administration to the petition of the Washington Legal Foundation. Restriction on the dissemination of off-label information; Information on off-label uses.

  • FDA remains firm on 'highlights' in drug labels. Dickinson, James G. // Medical Marketing & Media;Jun2002, Vol. 37 Issue 6, p30 

    Reports on the proposal of the Food and Drug Administration on the inclusion of highlights section of package inserts in the U.S. Summary of important prescribing information; Approval of labelling; Increase of liability exposure.

  • Professor urges drug label comprehension tests. Dickinson, James G. // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p30 

    Reports on the encouragement of drug label comprehension tests for drug application submitted to the Food and Drug Administration in the U.S. Focus on warning labels; Compliance of the First Amendment obligations; Assessment of the regulatory responsibilities.

  • GnRH labeling update.  // Monthly Prescribing Reference;Dec2010, Vol. 26 Issue 12, pA18 

    The article reports that the Food and Drug Administration (FDA) requested manufacturers of Gonadotropin-Releasing Hormone (GnRH) to include safety information on its Warning and Precautions section of its drug label in the U.S.

  • Warning Labels Getting Larger.  // Paper, Film & Foil Converter;Dec2010, Vol. 84 Issue 12, p26 

    The article focuses on the U.S. Food and Drug Administration's (FDA) new regulation that will require the cigarette's package to have warning label on the upper portion of the front and rear panels and must comprise at least 50 percent of it.

  • Black box warning added to Xeloda. Dickinson, James G. // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p22 

    Reports on the black box warning added to the drug Xeloda by the U.S. Food & Drug Administration (FDA). Complications brought by Xeloda; Precaution of the FDA for Xeloda.

  • Senate reauthorizes pediatric exclusivity. Dickinson, James G. // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p24 

    Reports on the authorization of the pediatric labeling program of the Food and Drug Administration in the U.S.

  • FDA Actions.  // Critical Care Alert;May2009 Pharmacology Watch, p2 

    The article reports on the requirement of the U.S. Food and Drug Administration (FDA) on manufacturers of metaclopramide to include a box warning concerning the risk of long term or high-dose use and tardive duskinesia in their labeling.

  • News in brief….  // Reactions Weekly;8/6/2005, Issue 1063, p2 

    Presents updates on issues and events concerning the global pharmaceutical industry as of August 2005. Issuance of a Public Advisory warning against the use of Paxil or Paxil controlled-release in combination with pimozide in Canada; Completion of the revised label for Celebrex by the U.S. Food...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics